Library Screening Services

Enjoy the convenience of outsourced high-throughput screening with ready access to a portfolio of more than 1000 highly validated and robust assays that can be deployed for testing against compound collections of any size. Outsource with confidence knowing that our assays are performed under highly standardized conditions using best-in-class lab automation to provide exceptional assay performance and reproducible data. Our library screening services save you time and frees up internal resources to focus on other high value discovery activities. From single target HTS to library profiling and follow-up services, DiscoveRx delivers high quality data that ensures project timelines are met and maximizes the discovery of potent & selective lead compounds for new drug discovery programs.

Library Screening Features and Benefits

  • Comprehensive menu of over 1000 validated assays
  • Capacity to screen more than 100,000 wells/day
  • Flexible: screen any number of compounds against any number of targets
  • Accurate, precise & reproducible data
  • Rapid data turnaround
  • Identify potent and selective high quality leads in a single screen
  • Identify new target opportunities from existing chemical assets
  • Free internal resources to focus on other activities

Accurate, Precise & Reproducible Data

LeadHunter Discovery Services partners have long recognized that accurate, precise and reproducible data are critical components of the discovery and development process and are the cornerstone of a successful screening partnership. All our assays undergo thorough validation prior to being released into production and assay performance is continually monitored to ensure accurate pharmacology and data consistency.

Learn what our customers are saying in peer reviewed publications:

  • KINOMEscan team and from our partners
  • PathHunter Arrestin
ErbB1 receptor and dose dependent inhibition  
Vehicle tolerance is determined as part of the assay validation process prior to every screen.
Plate uniformity data for a typical screen run in antagonist mode. Results show excellent performance with an average Z' of 0.7, 47% inhibition for control antagonist IC50, and overall hit rate of 1.5%.

ErbB1 receptor and dose dependent inhibition


Average Z’ values and standard deviations were calculated for each kinase based on fourteen control wells per experiment in over 135 independent experiments spanning a period of sixteen months. Average Z' = 0.71.
Profiling of the indicated compounds at 10uM in fourteen independent experiments against 442 kinases over a one year period. Correlation analysis was performed in a pair-wise comparison to calculate the correlation coefficient. The correlation coefficients range from 0.91 to 0.97 with an average of 0.95.